Correction of the Mutation Responsible for Sickle Cell Anemia by an RNA-DNA Oligonucleotide

See allHide authors and affiliations

Science  06 Sep 1996:
Vol. 273, Issue 5280, pp. 1386-1389
DOI: 10.1126/science.273.5280.1386


A chimeric oligonucleotide composed of DNA and modified RNA residues was used to direct correction of the mutation in the hemoglobin βS allele. After introduction of the chimeric molecule into lymphoblastoid cells homozygous for the βS mutation, there was a detectable level of gene conversion of the mutant allele to the normal sequence. The efficient and specific conversion directed by chimeric molecules may hold promise as a therapeutic method for the treatment of genetic diseases.